April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Clinical Heidenhain Variant of Sporadic Creutzfeldt-Jakob Disease (CJD) With Co-Occurrence of Prion Protein Types 1 and 2
Author Affiliations & Notes
  • A. M. Alizai
    Ophthalmology, Temple University Hospital, Philadelphia, Pennsylvania
  • G. Puoti,
    Pathology, National Prion Disease Surveillance Center, Case Western Reserve University, Cleveland, Ohio
  • P. Gambetti
    Pathology, National Prion Disease Surveillance Center, Case Western Reserve University, Cleveland, Ohio
  • I. Cali
    Pathology, National Prion Disease Surveillance Center, Case Western Reserve University, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  A.M. Alizai, None; G. Puoti,, None; P. Gambetti, None; I. Cali, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5476. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. M. Alizai, G. Puoti,, P. Gambetti, I. Cali; Clinical Heidenhain Variant of Sporadic Creutzfeldt-Jakob Disease (CJD) With Co-Occurrence of Prion Protein Types 1 and 2. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5476.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Sporadic Creutzfeldt-Jacob disease (sCJD) is a rare neurodegenerative illness comprising five phenotypically distinct subtypes based on the methionine(M)/valine(V) polymorphism at codon 129 of the prion protein (PrP) gene and presence of either one of the two protease-resistant PrP (PrPres), referred to as PrPres type 1 and type 2.1, 2 The most common of these five subtypes includes the sCJDMM(MV)1 that matches the "classic" sCJD and comprises the so-called Heidenhain variant (HsCJD) characterized by early and prominent visual symptoms. Recently, an additional subtype of sCJD has been described and identified as sCJDMM1-2 in which both types 1 and 2 histopathological changes are found in the same brain.3 The clinical Heidenhain phenotype in association with histopathological sCJDMM1-2 subtype has not been described before.

Methods: : Clinical, neuroimaging, EEG findings, histopathological and immunostaining as well as PrPres characterization of 20 cases of sCJDMM1-2 were reviewed.

Results: : Two cases (10%) of HsCJD with ages at onset of 51 and 66 years and disease durations of 4 and 12 months were identified. Immunohistopathology and PrPres type determination were consistent with the features of the sCJDMM1-2 subtype.3 The visual cortex was more severely affected than the frontal cortex and was found to carry both PrPres types.4 The study of the quantitative distribution of PrPres types, expressed as mean percentage of total PrPres types 1 and 2 (1:2), was 79%:21% for the sCJDMM1-2 with 4 month and 45%:55% for the case with 12 months disease duration respectively. The cerebellum showed both PrPres types and PrP immunohistochemical patterns of the sCJDMM1-2.

Conclusions: : To our knowledge, this is the first histopathological finding of sCJDMM1-2 in Heidenhain variant of sporadic CJD.Also, the amount of PrPres type 2 and to a lesser extent that of the MM2-like immunohistochemical features increase with the disease duration, as seen for the sCJDMM1-2, which may have prognostic implications.

Keywords: neuro-ophthalmology: diagnosis • immunohistochemistry • pathology: human 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×